Docoh
Loading...

AMPE Ampio Pharmaceuticals

News

Pro users get this 30m faster
Ampio Pharmaceuticals Granted U.S. Patent Titled 'Methods for treating diseases associated with respiratory viruses'
28 Sep 21
News, Legal
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5276&f=G&l=50&d=PTXT&p=106&S1=20210928&OS=20210928&RS=20210928
Ampio To Test Inhaled COVID-19 Treatment In India
21 Sep 21
Biotech, News, Penny Stocks, Health Care, Small Cap, Movers, Trading Ideas, General
Ampio Pharma Reports Received Approval From Drugs Controller General Of India To Begin AP-019 Phase 2 Study In India
21 Sep 21
Biotech, News, FDA, General
Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced regulatory approval from the Drugs
Why Ampio Pharmaceuticals Stock Is Trading Higher Today
15 Sep 21
News, FDA
Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading higher Wednesday after the company announced top-line results from the AP-013 Phase III study of Ampion in patients suffering from severe osteoarthritis of the knee (OAK).
EXCLUSIVE: Ampio's Ampion Shows Benefit In Late-Stage Knee Osteoarthritis Study
15 Sep 21
Biotech, News, Penny Stocks, Health Care, Exclusives, General
Ampio Pharmaceuticals Inc (NYSE: AMPE) has reported top-line results from the AP-013 Phase 3 trial evaluating the Company's intra-articular (IA) injection of Ampion in adults with pain due to severe osteoarthritis of the knee (OAK).
Ampio Pharmaceuticals Announces New Research Manuscript On Anti-Inflammatory Mode Of Action
13 Aug 21
Biotech, General
Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options,
Ampio Pharmaceuticals Q2 EPS $(0.02), Inline
4 Aug 21
Earnings, News
Ampio Pharmaceuticals (AMEX:AMPE) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
Earnings Scheduled For August 4, 2021
4 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
Ampio To Present At October Scientific Conference Evidence Of Ampion's Role In Treating Lupus Nephritis, COVID-19
28 Jul 21
Biotech, News, Penny Stocks, Exclusives, General
Ampio Pharmaceuticals, Inc. (NYSE: AMPE), a biopharma developing immunotherapies for inflammatory conditions, is set to present data on lead drug Ampio at a scientific conference.
EXCLUSIVE: Ampio Pharma Highlights Upcoming Presentation Of Data For Ampion At Int'l. Congress On Systemic Lupus Ertyhematosus, Oct. 6-9, 2021
28 Jul 21
News, FDA, Exclusives
Ampio Pharmaceuticals to Present at the 14 th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) & 6 th International Congress on Controversies in Rheumatology and Autoimmunity

Press releases

Pro users get this 30m faster
Ampio Pharmaceuticals Strengthens Management Team and Board of Directors
13 Oct 21
Press Releases
ENGLEWOOD, Colo., Oct. 13, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today
Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India
21 Sep 21
Press Releases
ENGLEWOOD, Colo., Sept. 21, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today
Ampio Pharmaceuticals Announces Top-line Results from AP-013 Phase III Study of Ampion in Adult Patients Suffering from Severe Osteoarthritis of the Knee (OAK)
15 Sep 21
Press Releases
ENGLEWOOD, Colo., Sept. 15, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today
Ampio Pharmaceuticals Announces Important New Research Manuscript on Anti-Inflammatory Mode of Action
13 Aug 21
Press Releases
ENGLEWOOD, Colo., Aug. 13, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for
Ampio Pharmaceuticals Reminds Stockholders to Vote Shares in Advance of 2021 Annual Meeting
12 Aug 21
Press Releases
ENGLEWOOD, Colo., Aug. 12, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for
Ampio Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
11 Aug 21
Press Releases
ENGLEWOOD, Colo., Aug. 11, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for
Thinking about buying stock in Ampio Pharmaceuticals, Stratasys, Zymergen, Himax Technologies, or Genius Sports?
5 Aug 21
Opinion, Press Releases
NEW YORK, Aug. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMPE, SSYS, ZY, HIMX, and GENI.
Ampio Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate Update
4 Aug 21
Earnings, Press Releases
ENGLEWOOD, Colo., Aug. 4, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which
Ampio Pharmaceuticals to Present at the American College of Toxicology 42nd Annual Meeting
29 Jul 21
Press Releases
ENGLEWOOD, Colo., July 29, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today
Ampio Pharmaceuticals to Present at the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) & 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA)
28 Jul 21
Press Releases
ENGLEWOOD, Colo., July 28, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today
Ampio Pharmaceuticals to Present at Aspen Lung Conference
27 Jul 21
Press Releases
ENGLEWOOD, Colo., July 27, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today